Antimalarial cytoskeletal targeting with broad apicomplexan activity

D Darshan V. Trivedi (Kainomyx Inc.) A Anastasia Karabina (Kainomyx Inc.) T Tiantian Jiang (Department of Pediatrics, School of Medicine, University of California) D Daisy Chen N Nimisha Mittal (Department of Pediatrics, School of Medicine, University of California San Diego) T Tonnie Huijs (TropIQ Health Sciences) R Rianne van der Laak (TropIQ Health Sciences) J Jin H. Jeon (Department of Microbiology and Immunology, Columbia University Medical Center) T Tomas Yeo D Dihia Moussaoui (Cell Biology and Cancer Unit, Structural Motility, Institut Curie, UMR144 CNRS, Paris Science & Letters Research University) J James P. Robblee (Department of Molecular Physiology and Biophysics, University of Vermont) M Marianna Akey (Department of Molecular Microbiology, Washington University School of Medicine) M Matthew Freese (Department of Molecular Microbiology, Washington University School of Medicine) L Lorraine Fuller (Department of Poultry Science, College of Agricultural & Environmental Sciences, University of Georgia) G Gustave Bergnes (Kainomyx Inc.) A Alice Racca (Kainomyx Inc.) H Heba Wander (Kainomyx Inc.) S Seongwon Jung (Kainomyx Inc.) S Stephanie Ouchida (Kainomyx Inc.) P Paul V. Ruijgrok (Kainomyx Inc.) D Dan Song (Kainomyx Inc.) A Annamma Spudich (Kainomyx Inc.) K Kathleen M. Ruppel (Department of Biochemistry, Stanford University School of Medicine) S Suman Nag (Kainomyx Inc.) C Christoph Mueller-Dieckmann (Structural Biology Group, European Synchrotron Radiation Facility) J Jeremy N. Burrows B Benoît Laleu (Medicines for Malaria Venture Medicines for Malaria Venture, International Center Cointrin) R Rafael Victorio Carvalho Guido (São Carlos of Physics Institute, University of São Paulo) A Anna Caroline Campos Aguiar (Department of Microbiology, Immunology and Parasitology Federal University of São Paulo) D Dhelio Batista Pereira (Research Center Tropical Medicine of Rondônia) S Sergio Wittlin (Swiss Tropical and Public Health Institute) P Partha Mukherjee (The Chatterjee Group Life Sciences Pvt. Ltd.) A Arnish Chakraborty (The Chatterjee Group Life Sciences Pvt. Ltd.) S Samuel E. Aggrey (Department of Poultry Science, College of Agricultural & Environmental Sciences, University of Georgia) J Julien Robert-Paganin (Cell Biology and Cancer Unit, Structural Motility, Institut Curie, UMR144 CNRS, Paris Science & Letters Research University) K Kathleen M. Trybus (Department of Molecular Physiology and Biophysics, University of Vermont) L L. David Sibley A Anne Houdusse (Structural Motility, Institut Curie, Université Paris Sciences et Lettres, Sorbonne Université, CNRS UMR144) D David A. Fidock (Department of Microbiology and Immunology, Columbia University Medical Center) K Koen J. Dechering E Elizabeth A. Winzeler J James A. Spudich (Department of Biochemistry, Stanford University School of Medicine)

Abstract

Malaria is a devastating disease that resulted in an estimated 610,000 deaths in 2024, the majority being children under the age of five. Here, we use KNX-115 to illustrate multistage antiparasitic activity upon targeting the cytoskeletal enzyme Plasmodium falciparum myosin A (PfMyoA). KNX-115 inhibits purified actin-activated ATPase with a potency in the low nanomolar range and >50-fold selectivity against cardiac, skeletal, and smooth muscle myosins. KNX-115 traps PfMyoA in a state that binds weakly to actin. A 2.35 Å resolution structure of KNX-115 bound to PfMyoA reveals critical interactions contributing to its mechanism of action. Importantly, in vitro evolution data reveal that KNX-115 engages PfMyoA as a sole cellular target. Inhibiting PfMyoA blocks the development of the blood and liver stages of laboratory strains of P. falciparum , with no liver cell toxicity, sporozoite cell traversal and motility, and sporozoite development in the mosquito. Inhibiting PfMyoA completely kills parasites after 96 h of treatment. Furthermore, KNX-115 is equally effective at inhibiting a panel of Plasmodium strains resistant to experimental and marketed antimalarials and shows inhibitory activity against P. falciparum circulating isolates from the Brazilian Amazon. Inhibiting PfMyoA with KNX-115 also blocks the blood stage of a laboratory strain of Plasmodium vivax . In line with the evolutionary identity of MyoA among various apicomplexan parasites, KNX-115 also inhibits Cryptosporidium and Eimeria MyoA in vitro and is an effective inhibitor of Cryptosporidium , Toxoplasma, and Eimeria cellular growth, with EC 50 s similar to those found for blood and liver stage Plasmodium .

Article Details

Volume / Issue Vol. 123, Issue 30
Published July 28, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (42)

D

Darshan V. Trivedi

Kainomyx Inc.

A

Anastasia Karabina

Kainomyx Inc.

T

Tiantian Jiang

Department of Pediatrics, School of Medicine, University of California

D

Daisy Chen

N

Nimisha Mittal

Department of Pediatrics, School of Medicine, University of California San Diego

T

Tonnie Huijs

TropIQ Health Sciences

R

Rianne van der Laak

TropIQ Health Sciences

J

Jin H. Jeon

Department of Microbiology and Immunology, Columbia University Medical Center

T

Tomas Yeo

D

Dihia Moussaoui

Cell Biology and Cancer Unit, Structural Motility, Institut Curie, UMR144 CNRS, Paris Science & Letters Research University

J

James P. Robblee

Department of Molecular Physiology and Biophysics, University of Vermont

M

Marianna Akey

Department of Molecular Microbiology, Washington University School of Medicine

M

Matthew Freese

Department of Molecular Microbiology, Washington University School of Medicine

L

Lorraine Fuller

Department of Poultry Science, College of Agricultural & Environmental Sciences, University of Georgia

G

Gustave Bergnes

Kainomyx Inc.

A

Alice Racca

Kainomyx Inc.

H

Heba Wander

Kainomyx Inc.

S

Seongwon Jung

Kainomyx Inc.

S

Stephanie Ouchida

Kainomyx Inc.

P

Paul V. Ruijgrok

Kainomyx Inc.

D

Dan Song

Kainomyx Inc.

A

Annamma Spudich

Kainomyx Inc.

K

Kathleen M. Ruppel

Department of Biochemistry, Stanford University School of Medicine

S

Suman Nag

Kainomyx Inc.

C

Christoph Mueller-Dieckmann

Structural Biology Group, European Synchrotron Radiation Facility

J

Jeremy N. Burrows

B

Benoît Laleu

Medicines for Malaria Venture Medicines for Malaria Venture, International Center Cointrin

R

Rafael Victorio Carvalho Guido

São Carlos of Physics Institute, University of São Paulo

A

Anna Caroline Campos Aguiar

Department of Microbiology, Immunology and Parasitology Federal University of São Paulo

D

Dhelio Batista Pereira

Research Center Tropical Medicine of Rondônia

S

Sergio Wittlin

Swiss Tropical and Public Health Institute

P

Partha Mukherjee

The Chatterjee Group Life Sciences Pvt. Ltd.

A

Arnish Chakraborty

The Chatterjee Group Life Sciences Pvt. Ltd.

S

Samuel E. Aggrey

Department of Poultry Science, College of Agricultural & Environmental Sciences, University of Georgia

J

Julien Robert-Paganin

Cell Biology and Cancer Unit, Structural Motility, Institut Curie, UMR144 CNRS, Paris Science & Letters Research University

K

Kathleen M. Trybus

Department of Molecular Physiology and Biophysics, University of Vermont

L

L. David Sibley

A

Anne Houdusse

Structural Motility, Institut Curie, Université Paris Sciences et Lettres, Sorbonne Université, CNRS UMR144

D

David A. Fidock

Department of Microbiology and Immunology, Columbia University Medical Center

K

Koen J. Dechering

E

Elizabeth A. Winzeler

J

James A. Spudich

Department of Biochemistry, Stanford University School of Medicine